Abstract
Whereas cognitive impairment is a common symptom in multiple brain disorders, predictive and highthroughput animal models of cognition and behavior are becoming increasingly important in the field of translational neuroscience research. In particular, reliable models of the cognitive deficits characteristic of numerous neurobehavioral disorders such as Alzheimer’s disease and schizophrenia have become a significant focus of investigation. While rodents have traditionally been used to study cognitive phenotypes, zebrafish (Danio rerio) are gaining popularity as an excellent model to complement current translational neuroscience research. Here we discuss recent advances in pharmacological and genetic approaches using zebrafish models to study cognitive impairments and to discover novel cognitive enhancers and neuroprotective mechanisms.
Keywords: Cognition, cognitive enhancers, drug screening, neurobehavioral disorders, neuroprotective agents, zebrafish
Current Neuropharmacology
Title:The Developing Utility of Zebrafish Models for Cognitive Enhancers Research
Volume: 10 Issue: 3
Author(s): Adam Michael Stewart and Allan V. Kalueff
Affiliation:
Keywords: Cognition, cognitive enhancers, drug screening, neurobehavioral disorders, neuroprotective agents, zebrafish
Abstract: Whereas cognitive impairment is a common symptom in multiple brain disorders, predictive and highthroughput animal models of cognition and behavior are becoming increasingly important in the field of translational neuroscience research. In particular, reliable models of the cognitive deficits characteristic of numerous neurobehavioral disorders such as Alzheimer’s disease and schizophrenia have become a significant focus of investigation. While rodents have traditionally been used to study cognitive phenotypes, zebrafish (Danio rerio) are gaining popularity as an excellent model to complement current translational neuroscience research. Here we discuss recent advances in pharmacological and genetic approaches using zebrafish models to study cognitive impairments and to discover novel cognitive enhancers and neuroprotective mechanisms.
Export Options
About this article
Cite this article as:
Michael Stewart Adam and V. Kalueff Allan, The Developing Utility of Zebrafish Models for Cognitive Enhancers Research, Current Neuropharmacology 2012; 10 (3) . https://dx.doi.org/10.2174/157015912803217323
DOI https://dx.doi.org/10.2174/157015912803217323 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Was Phenserine a Failure or Were Investigators Mislead by Methods?
Current Alzheimer Research P2Y Purinoceptors as Potential Emerging Therapeutical Target in Vascular Disease
Current Pharmaceutical Design Influence of Inosine on Cerebral Hemodynamics in Space Motion Sickness in Experimental Animals
Central Nervous System Agents in Medicinal Chemistry An Overview on Natural Cholinesterase Inhibitors - A Multi-Targeted Drug Class - and Their Mass Production
Mini-Reviews in Medicinal Chemistry Synaptic Plasticity, Metaplasticity and Depression
Current Neuropharmacology Depression as is Seen by Molecular Spectroscopy. Phospholipid- Protein Balance in Affective Disorders and Dementia
Current Molecular Medicine Editorial [Hot Topic: The Complex and Multifactorial Nature of Alzheimers Disease (Guest Editors: Karim Alkadhi and Jason Eriksen)]
Current Neuropharmacology Crocin Protects Against Beta-Amyloid Peptide-Induced Apoptosis in PC12 Cells Via the PI3 K Pathway
Current Molecular Pharmacology Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research Translational Methods for Non-Invasive Electrical Stimulation to Facilitate Gait Rehabilitation Following Stroke - The Future Directions
Neuroscience and Biomedical Engineering (Discontinued) Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis
CNS & Neurological Disorders - Drug Targets Poor Nutrition with Aging: an “Oxidatively Stressing” Condition
Current Nutrition & Food Science MicroRNAs in Cardiovascular Therapeutics
Current Topics in Medicinal Chemistry Gender and Cardiovascular Mortality in Northern and Southern European Populations
Current Pharmaceutical Design Anti-Seizure Medications and Estradiol for Neuroprotection in Epilepsy: The 2013 Update
Recent Patents on CNS Drug Discovery (Discontinued) Metal Ions and Metal Complexes in Alzheimer’s Disease
Current Pharmaceutical Design Radiopharmaceuticals in Neurological and Psychiatric Disorders
Current Clinical Pharmacology ADAM Proteases: Protective Role in Alzheimers and Prion Diseases ?
Current Alzheimer Research Potential New Targets for Antithrombotic Therapy
Current Pharmaceutical Design